Crystalline 1H-imidazo[4,5-b]pyridin-5-amine,...

Details Crystalline 1H-imidazo[4,5-b]pyridin-5-amine,... Crystalline 1H-imidazo[4,5-b]pyridin-5-amine,...

2006-02-01

2010-02-02

Desai, Rita J (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S303000

Reexamination Certificate

active

07655800

ABSTRACT:
The invention relates to crystalline 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate, E6070, its method of preparation, and its therapeutic uses. Pharmaceutical compositions containing crystalline E6070 and a pharmaceutically acceptable carrier represent one embodiment of the invention. The invention also relates to methods for treating an inflammatory disorder, an autoimmune disorder, or a proliferative disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of crystalline E6070.

REFERENCES:
patent: 6860940 (2005-03-01), Segelke et al.
patent: 7015041 (2006-03-01), Santarsiero et al.
patent: 7052545 (2006-05-01), Quake et al.
patent: 7195670 (2007-03-01), Hansen et al.
patent: 7214540 (2007-05-01), DeLucas et al.
patent: 7229500 (2007-06-01), Haushalter et al.
patent: 2004/0186127 (2004-09-01), Daun et al.
patent: WO 03/057696 (2003-07-01), None
patent: WO 2004/063336 (2004-07-01), None
Gatterman, Ludwig The Practical Methods of Organic Chemistry 1896, MacMillan: New York, pp. 1-14.
Berge “Pharmaceutical Salts” Journal of Pharmaceutical Sciences 1977, 66, 1-19.
Morissette et. al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids” Advanced Drug Delivery Reviews 2004, 56, 275-300.
Pudipeddi et. al. “Trends in Solubility of Polymorphs” Journal of Pharmaceutical Sciences, May 2005, 94, 929.
Hillery et. al. Drug delivery and targeting for pharmacists and pharmaceutical scientists Taylor and Francis 2001, p. 29.
International Search Report, Dated May 24, 2006.
Brown, Joan Heller, et al., “Muscarinic Receptor Agonists and Antagonists,”Goodman and Gilman's The Pharmacological Basis of Therapeutics, Tenth Edition, A. Gilman, J. Hardman and L. Limird, eds., McGraw-Hill Press, pp. 155-173, 2001.
Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), Table of Contents.
Tak, Paul P. et al., NF-κB: a key role in inflammatory diseases—NF-κB in Defense and Disease,The Journal of Clinical Investigation, Jan. 2001, vol. 107, pp. 7-11.

Affiliated with

Also associated with

Rating

Crystalline 1H-imidazo[4,5-b]pyridin-5-amine,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline 1H-imidazo[4,5-b]pyridin-5-amine,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline 1H-imidazo[4,5-b]pyridin-5-amine,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4162348